Serum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients

To evaluate the development of coronavirus disease 2019 (COVID-19), the roles of interleukin 6 (IL-6) and procalcitonin (PCT) were assessed to diagnose severe COVID-19. Between January and February 2020, 100 consecutive patients with confirmed COVID-19 were included and divided into common (n = 56),...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jinsong, Lin, Jingtao, Zhang, Erying, Zhong, Mengru, Luo, Yong, Fu, Yong, Yang, Yewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183731/
https://www.ncbi.nlm.nih.gov/pubmed/34087864
http://dx.doi.org/10.1097/MD.0000000000026131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183731/
https://www.ncbi.nlm.nih.gov/pubmed/34087864
http://dx.doi.org/10.1097/MD.0000000000026131

Ejemplares similares